retatrutide gip glp-1 glucagon receptor agonist vs. Tirzepatide: The Next-Gen Showdown Science Behind GLP 1 GIP

Abstract Nonalcoholic fatty liver disease (NAFLD) and its progressive form nonalcoholic steatohepatitis (NASH) are the hepatic expression of metabolic syndrome and may lead to serious injury to the liver resulting in cirrhosis and hepatocellular carcinoma (HCC)

For expensive drugs such as glucagon-like peptide 1 receptor agonists (GLP-1s), payer coverage is crucial for patient affordability

The results, expected to read out later this year, could support a brand-new Alzheimers treatment for the millions of people living with this disease

[PubMed] [Google Scholar] 15.Nauck M.A., Meier J.J

90 Allow for flexibility

Wilding et al., 2021) or the GIP/GLP-1 dual receptor agonist tirzepatide (Rosenstock et al., 2021